On May 1, 2026, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) based in Conshohocken, Pennsylvania, disclosed that it provided equity awards to 47 recently hired non-executive staff as inducement awards under the 2025 Inducement Plan. These awards were sanctioned by Madrigal's autonomous Compensation Committee following Nasdaq Listing Rule 5635(c)(4) guidelines. Madrigal focuses on creating innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH).